Aldesleukin (Proleukin)

General information

Class/mechanism: Recombinant interleukin-2 which activates the immune system. Aldesleukin encourages growth of IL-2 dependent cells, triggers natural killer (NK) and lymphokine-activated killer (LAK) cell activity, induces production of interferon gamma, and increases lymphocyte cytotoxicity.^[1]^[2]^[3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

5/5/1992: Initial approval for treatment of adults (>18 years old) with metastatic renal cell carcinoma

Also known as

Generic names: Interleukin-2, IL-2
Brand names: Macrolin, Proleukin

References

[insert-1] 1.0 ^1.1 Aldesleukin (Proleukin) package insert

[2] Aldesleukin (Proleukin) package insert (locally hosted backup)

[3] Proleukin manufacturer's website

[4] Aldesleukin (Proleukin) patient drug information (Chemocare)

[5] Aldesleukin (Proleukin) patient drug information (UpToDate)

[6] Aldesleukin (Proleukin) Package Insert

[1]

[2]

[3]

[4]

[5]

[6]